MarginsXMarginsX
Home › Markets › Health Care › COYA

Coya Therapeutics Inc. (COYA)

COYA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.00
-4.15% on the day
Market cap
$70.4M
Micro cap
Revenue · 2025
$7.9M
+123.6% on 2024
Net income · 2025
-$21.2M
-267.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/0001193125-26-107281-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCOYA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2022
SEC CIK0001835022
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$7.9M
Net income-$21.2M
Operating income-$22.6M
Net margin-267.1%
Operating margin-283.9%
Revenue growth+123.6%
Cash$46.8M
Total assets$50.0M
P/E (computed)Net income was not positive
P/S (computed)8.9×

Warning signs

Cash runway
19.7 months
$35.8M cash at September 30, 2026
Share count, 1 year
+12.1%
2025-11-10 to 2026-11-05 · +133.9% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result of these conditions, substantial doubt exists about the Company's ability to continue as a going concern."
10-Q 2026-11-10
Cash and burn$35.8M cash; operating cash flow -$5.5M a quarter.Report 2026-09-30
Shares outstanding23,457,849 (2026-11-05); 20,924,456 a year earlier; 10,030,436 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-05-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorWeaver and Tidwell, L.L.P., New York, New York, United StatesPCAOB Form AP 2026-03-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$234K-$10.6M-$7.2M$35.8MNo debt tags$4.7M10-Q 2026-11-10
Q2 2026
2026-06-30
$244K-$6.6M-$7.4M$43.2MNo debt tags$8.0M10-Q 2026-08-11
Q1 2026
2026-03-31
$251K-$7.2M-$6.2M$50.7MNo debt tags$7.9M10-Q 2026-05-12
Q4 2025
2025-12-31
$4.0M-$5.7M-$1.0M$46.8MNo debt tags$7.9M10-K 2026-03-16
Q3 2025
2025-09-30
$3.6M-$2.1M-$1.1M$28.1MNo debt tags$4.0M10-Q 2026-11-10
Q2 2025
2025-06-30
$164K-$6.1M-$5.8M$29.8MNo debt tags$423K10-Q 2026-08-11
Q1 2025
2025-03-31
$258K-$7.3M-$2.8M$35.5MNo debt tags$3.7M10-Q 2026-05-12
Q4 2024
2024-12-31
$2K-$2.9M-$2.4M$38.3MNo debt tags$3.6M10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-12
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-05-13

Source: SEC EDGAR submissions feed, 232 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.7%
1 month-30.1%
3 months-33.0%
Year to date-46.0%
1 year-47.5%
From 52-week high-51.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
VTVTvTv Therapeutics Inc.$17.69-10.16%$71.0M
CRBPCorbus Pharmaceuticals Holdings Inc.$3.38-0.44%$69.5M
MNOVMedicinova Inc$1.34-3.94%$68.7M
ZYBTZhengye Biotechnology Holding Limited$1.43-4.67%$67.8M
TLSATiziana Life Sciences Ltd. Common Shares$0.5762+1.11%$73.3M
TENXTenax Therapeutics Inc.$1.48-8.64%$67.4M
GOSSGossamer Bio Inc.$10.98+0.09%$67.2M
KALAKALA BIO Inc.$3.83-8.02%$74.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier